Pharmacogenetics and Cancer Chemotherapy

A ALHADITHY, N DEBOER, L DERIJKS, J ESCHER, C MULDER, J BROUWERS, Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Digestive and Liver Disease. ,vol. 37, pp. 282- 297 ,(2005) , 10.1016/J.DLD.2004.09.029

Zacharenia Saridaki, Vassilis Georgoulias, John Souglakos, Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer World Journal of Gastroenterology. ,vol. 16, pp. 1177- 1187 ,(2010) , 10.3748/WJG.V16.I10.1177

Brady Stein, B. Douglas Smith, Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib Clinical Therapeutics. ,vol. 32, pp. 804- 820 ,(2010) , 10.1016/J.CLINTHERA.2010.05.003

Minoli A Perera, Federico Innocenti, Mark J Ratain, Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. ,vol. 28, pp. 755- 768 ,(2008) , 10.1592/PHCO.28.6.755

Kazuma Kiyotani, Taisei Mushiroda, Naoya Hosono, Tatsuhiko Tsunoda, Michiaki Kubo, Fuminori Aki, Yutaka Okazaki, Koichi Hirata, Yuichi Takatsuka, Minoru Okazaki, Shozo Ohsumi, Takashi Yamakawa, Mitsunori Sasa, Yusuke Nakamura, Hitoshi Zembutsu, Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenetics and Genomics. ,vol. 20, pp. 565- 568 ,(2010) , 10.1097/FPC.0B013E32833AF231

Kostandinos Sideras, James N. Ingle, Matthew M. Ames, Charles L. Loprinzi, David P. Mrazek, John L. Black, Richard M. Weinshilboum, John R. Hawse, Thomas C. Spelsberg, Matthew P. Goetz, Coprescription of Tamoxifen and Medications That Inhibit CYP2D6 Journal of Clinical Oncology. ,vol. 28, pp. 2768- 2776 ,(2010) , 10.1200/JCO.2009.23.8931

C. M Kelly, D. N Juurlink, T. Gomes, M. Duong-Hua, K. I Pritchard, P. C Austin, L. F Paszat, Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ. ,vol. 340, ,(2010) , 10.1136/BMJ.C693

Pasi A. Jänne, Nathanael Gray, Jeff Settleman, Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nature Reviews Drug Discovery. ,vol. 8, pp. 709- 723 ,(2009) , 10.1038/NRD2871

A Lièvre, H Blons, P Laurent-Puig, Oncogenic mutations as predictive factors in colorectal cancer Oncogene. ,vol. 29, pp. 3033- 3043 ,(2010) , 10.1038/ONC.2010.89

J M Rae, , M J Sikora, N L Henry, L Li, S Kim, S Oesterreich, T C Skaar, A T Nguyen, Z Desta, A M Storniolo, D A Flockhart, D F Hayes, V Stearns, Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Pharmacogenomics Journal. ,vol. 9, pp. 258- 264 ,(2009) , 10.1038/TPJ.2009.14